Is Novartis India a good stock to invest in?

Novartis India can be analyzed on the following key metrics - TTM P/E: 31.62 Sector P/E: 31.15 Dividend Yield: 2.44% D/E ratio: -

Novartis India Share Price

Sector: Biotechnology & Drugs

Powered by

1024.35 +1.45 (0.14%)

1D
5D
1M
3M
6M
1Y
5Y
MAX

Price Range

Today’s Low 992.65

Today’s High 1041.95

52 Week Low 685

52 Week High 1248

Key Metrics

Market Cap (In Cr) 2525.62
Beta 0.67
Div. Yield (%) 2.44
P/B 3.39
TTM P/E 31.62
Peg Ratio 0.48
Sector P/E 31.15
D/E 0.01
Open Price 1016.25
Prev Close 1022.9

View All Metrics

Novartis India Analysis

Price Analysis

1 Week

-2.52%
3 Months

-6.84%
6 Month

-6.16%
YTD

32.29%
1 Year

46.66%

Risk Meter

28% Low risk
28% Moderate risk
28% Balanced Risk
28% High risk
28% Extreme risk

Novartis India News

Premium

Novartis India Q2 Results Live: Profit Falls by 13.81% YOY

1 min read . 27 Oct 2024

Companies reporting results on Tuesday, 30 July include Tata Consumer Products, Indian Oil Corporation, Exide Industries, GAIL, Titagarh Rail Systems, Indus Towers, Jindal Stainless, Dixon Tech, Granules India, Macrotech Developers, Castrol India, Shyam Metalics, Star Insurance, RR Kabel, Sapphire Foods, Lloyds Metals & Energy, Torrent Power, TVS Supply Chain Solutions, and Varun Beverages, among others. (Photo: AP)

Premium

Stocks to watch: HPCL, Colgate, Pfizer, ACC, Kansai Nerolac, BEL, Arvind

8 min read . 30 Jul 2024

Companies reporting results on May 13 include UPL, DLF, Zomato, Jindal Steel & Power, Varun Beverages, Aditya Birla Capital, BLS E-Services, Chalet Hotels, GIC Housing Finance, Ind-Swift Laboratories, INOX India, C E Info Systems, and Tube Investments of India, among others.

Premium

Stocks to watch: Tata Motors, ICICI Bank, Vedanta, Piramal Enterprises, Zomato

7 min read . 13 May 2024

The company’s plans are underway for the launch of the treatment in the country before the end of the current month.

Premium

Novartis set to launch chronic myeloid leukemia drug in India

2 min read . 14 Mar 2024

View More News

Novartis India Financials

INCOME
BALANCE SHEET
Cashflow

DATE

Annual

Quarterly

Period
2024

Total Revenue
335.07

Selling/ General/ Admin Expenses Total
23.13

Depreciation/ Amortization
2.61

Other Operating Expenses Total
46.84

Total Operating Expense
272.42

Operating Income
62.65

Net Income Before Taxes
122.84

Net Income
85.19

Diluted Normalized EPS
34.5

Period
2023

Total Revenue
378.74

Selling/ General/ Admin Expenses Total
97.05

Depreciation/ Amortization
6.06

Other Operating Expenses Total
10.93

Total Operating Expense
318.66

Operating Income
60.08

Net Income Before Taxes
115.38

Net Income
103.36

Diluted Normalized EPS
40.81

Period
2022

Total Revenue
399.87

Selling/ General/ Admin Expenses Total
188.65

Depreciation/ Amortization
9.65

Other Operating Expenses Total
2.5

Total Operating Expense
431.91

Operating Income
-32.04

Net Income Before Taxes
-3.82

Net Income
-3.72

Diluted Normalized EPS
11.6

Period
2021

Total Revenue
381.35

Selling/ General/ Admin Expenses Total
197.1

Depreciation/ Amortization
12.16

Other Operating Expenses Total
7.69

Total Operating Expense
366.58

Operating Income
14.77

Net Income Before Taxes
40.04

Net Income
20.9

Diluted Normalized EPS
7.5

Period
2020

Total Revenue
438.25

Selling/ General/ Admin Expenses Total
231

Depreciation/ Amortization
13.14

Other Operating Expenses Total
7.91

Total Operating Expense
437.41

Operating Income
0.84

Net Income Before Taxes
28.64

Net Income
10.08

Diluted Normalized EPS
6.52

Period
2019

Total Revenue
490.68

Selling/ General/ Admin Expenses Total
264.36

Depreciation/ Amortization
3.18

Other Operating Expenses Total
8.38

Total Operating Expense
478.03

Operating Income
12.65

Net Income Before Taxes
85.77

Net Income
51.77

Diluted Normalized EPS
13.45

Period
2018

Total Revenue
563.89

Selling/ General/ Admin Expenses Total
306.07

Depreciation/ Amortization
2.53

Other Operating Expenses Total
11.17

Total Operating Expense
569.54

Operating Income
-5.65

Net Income Before Taxes
157.52

Net Income
78.36

Diluted Normalized EPS
24.84

View detailed financials

Forecast

Income Sheet (In Cr) Net Income Vs Revenue

Returns Metrics (In Cr) ROA Vs ROE

Forecast

Balance Sheet Asset vs Liability

Forecast

Cash Flow Operating vs Investing

Novartis India Technical

Moving Average SMA

5 Day1049.39
10 Day1061.82
20 Day1060.05

50 Day1072.81
100 Day1102.48
300 Day1061.61

Novartis India Peers

Price
Ratio

Name
Latest Price
Change
% Change
52W High
52W Low
Mkt. Cap

Indoco Remedies
299.5
-4.8
-1.58
416.95
286.5
2761.39

Suven Life Sciences
118
-2.8
-2.32
169
75.95
2573.27

Novartis India
1024.35
1.45
0.14
1248
685
2529.2

Panacea Biotec
414.75
19.15
4.84
398.95
112.7
2540.37

SMS Pharmaceuticals
240.5
-10.45
-4.16
398
114.2
2035.88

Novartis India Shareholding

Shareholding Pattern

Shareholding Trend

Shareholding(%) v/s Date

View All

Corporate Actions

Board Meeting
AGM
Dividends
Bonus
Split
Rights

Meeting Date
Purpose

25-Oct-24
Quarterly Results

10-May-24
Audited Results & Final Dividend

25-Jan-24
Quarterly Results

27-Oct-23
Quarterly Results

26-Jul-23
Quarterly Results

10-May-23
Audited Results, Final & Special Dividend

08-Feb-23
Quarterly Results

09-Nov-22
Quarterly Results

27-Jul-22
Quarterly Results

19-May-22
Audited Results & Final Dividend

Meeting Date
Announced on
Purpose

31-Jul-24
10-May-24
AGM

23-Mar-24
20-Feb-24
POM

29-Jul-22
19-May-22
AGM

27-Aug-21
17-Jun-21
AGM

25-Mar-21
22-Feb-21
POM

-
10-May-23
AGM

Announced on
Record Date
Ex-Dividend
Dividend Value

10-May-24
-
23-Jul-24
25

10-May-23
-
20-Jul-23
10

11-May-23
-
20-Jul-23
37.5

19-May-22
-
20-Jul-22
10

17-Jun-21
-
17-Aug-21
10

View All

Company Profile

ABOUT Novartis India

Industry Biotechnology & Drugs
ISIN INE234A01025
BSE Code 500672
NSE Code NOVARTIND

Novartis India Limited is an India-based company. The Company is engaged in the business of trading pharmaceuticals. The Company’s brands hold key positions in therapeutic areas, such as, in the bone and pain therapeutic area. Its brand is Voveran. In the transplantation immunology therapeutic area, the Company's brands include Simulect, Certican, Sandimmun, Neoral and Myfortic. In the neurosciences therapeutic area, its brands include Tegrital and Exelon.

MANAGEMENT

Shilpa Joshi Chief Financial Officer, Whole-Time Director
Chandni Maru Chief Compliance Officer, Company Secretary
Falin Ishwarlal Majmudar Additional Director (Whole-Time Director)

NOVARTIS INDIA SUMMARY

Novartis India is trading 0.14% upper at Rs 1024.35 as compared to its last closing price. Novartis India has been trading in the price range of 1041.95 & 992.65. Novartis India has given 32.29% in this year & -2.52% in the last 5 days.

Novartis India has TTM P/E ratio 31.62 as compared to the sector P/E of 31.15.

The company posted a net profit of 20.41 Crores in its last quarter.

Listed peers of Novartis India include Indoco Remedies (-1.58%), Suven Life Sciences (-2.32%), Novartis India (0.14%) etc.

Novartis India has a 70.68% promoter holding & 29.32% public holding.

FAQs about Novartis India

Novartis India is trading at 1024.35 as on 21 Nov, 2024 3:46:06 PM. This is 0.14% upper as compared to its previous closing price of 1022.9

The market capitalization of Novartis India is 2525.62 Cr as on 21 Nov, 2024 3:46:06 PM.

The 52 wk high for Novartis India is 1248 whereas the 52 wk low is 685

Novartis India can be analyzed on the following key metrics -

TTM P/E: 31.62
Sector P/E: 31.15
Dividend Yield: 2.44%
D/E ratio: -

Novartis India reported a net profit of 85.19 Cr in 2024.

Novartis India Quick Links

Equity Quick Links

Top Gainers | Top Losers | Indian Indices | BSE Active Stocks | NSE Active Stocks

Novartis India Share Price

Price Range

Price Range

Key Metrics

Novartis India Analysis

Novartis India News

Novartis India Q2 Results Live: Profit Falls by 13.81% YOY

Stocks to watch: HPCL, Colgate, Pfizer, ACC, Kansai Nerolac, BEL, Arvind

Stocks to watch: Tata Motors, ICICI Bank, Vedanta, Piramal Enterprises, Zomato

Novartis set to launch chronic myeloid leukemia drug in India

Novartis India Financials

Forecast

Forecast

Forecast

Novartis India Technical

Novartis India Peers

Novartis India Shareholding

Shareholding Pattern

Shareholding Trend

Corporate Actions

Company Profile

ABOUT Novartis India

MANAGEMENT

NOVARTIS INDIA SUMMARY

FAQs about Novartis India

Wait for it…

Wait for it…

Congratulations!

Subscribe to continue